In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

U.S. BIOSCIENCE ETHYOL DOES NOT DECREASE SURVIVAL RATE

Executive Summary

U.S. BIOSCIENCE ETHYOL DOES NOT DECREASE SURVIVAL RATE in patients with advanced epithelial ovarian cancer, John Click, MD, University of Pennsylvania, told the American Society of Clinical Oncology May 16 in Dallas. Click presented the results of a Phase III trial encompassing 200 ovarian cancer patients comparing treatment with a regimen of the chemoprotective agent Ethyol (amifostine) and the chemotherapy agents cyclophosphamide and cisplatin to treatment with cyclophosphamide and cisplatin alone.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS024524

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel